TABLE I.
Recommended doses and administration schedules for bone-targeted agents
| Agent | Indication | Creatinine clearance (mL/min) | Dose (mg) | Route | Schedule | Infusion rate |
|---|---|---|---|---|---|---|
| Zoledronate | mBCa and CRPC | >60 | 4 | Intravenous | Every 12 weeks or every 3–4 weeks18 | No less than 15 minutes |
| 50–59 | 3.5 | |||||
| 40–49 | 3.3 | |||||
| 30–39 | 3 | |||||
| <30 | Use not recommended | |||||
|
| ||||||
| Pamidronate | mBCa only | >90 | 90 | Intravenous | Every 3–4 weeks; may consider every 12 weeks18 | No less than 2 hours; 4 hours recommended |
| 30–90 | 90 | |||||
| <30 | Use not recommended | |||||
|
| ||||||
| Denosumab | mBCa and CRPC | NA | 120 | Subcutaneous | Every 3–4 weeks; may consider every 12 weeks36 | NA |
mBCa = metastatic breast cancer; CRPC = castration-resistant prostate cancer; NA = not applicable.